Replies to post #5692 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

Re: HCV market share in US

These are the reported 3Q25 and 2025-YTD US HCV sales for each company:

 
        3Q25   YoY     YTD   YoY 
 GILD  $146M  -34%   $497M  -33% 
 ABBV  $146M  flat   $472M   +3%

The trend is pretty clear!

https://investors.gilead.com/news/news-details/2025/Gilead-Sciences-Announces-Third-Quarter-2025-Financial-Results/default.aspx
https://www.prnewswire.com/news-releases/abbvie-reports-third-quarter-2025-financial-results-302600511.html